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A splicing isoform of TEAD4 attenuates the
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Aberrant splicing is frequently found in cancer, yet the biological consequences of such
alterations are mostly undefined. Here we report that the Hippo–YAP signalling, a key
pathway that regulates cell proliferation and organ size, is under control of a splicing switch.
We show that TEAD4, the transcription factor that mediates Hippo–YAP signalling, under-
goes alternative splicing facilitated by the tumour suppressor RBM4, producing a truncated
isoform, TEAD4-S, which lacks an N-terminal DNA-binding domain, but maintains YAP
interaction domain. TEAD4-S is located in both the nucleus and cytoplasm, acting as a
dominant negative isoform to YAP activity. Consistently, TEAD4-S is reduced in cancer cells,
and its re-expression suppresses cancer cell proliferation and migration, inhibiting tumour
growth in xenograft mouse models. Furthermore, TEAD4-S is reduced in human cancers, and
patients with elevated TEAD4-S levels have improved survival. Altogether, these data reveal a
splicing switch that serves to fine tune the Hippo–YAP pathway.
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H
ippo–YAP signalling is a key pathway that regulates cell
proliferation, cell contact inhibition and organ size1–3.
The transcriptional output of this pathway is mediated by
TEAD proteins that partner with YAP to activate genes that
stimulate cell proliferation4,5. As a key effector of the Hippo
pathway, YAP lacks DNA-binding motif, and thus recognizes its
targets through interacting with TEAD proteins6. Under normal
condition, YAP is translocated into the nucleus to promote
cell growth; however, the activation of Hippo causes YAP
phosphorylation, leading to cytoplasmic retention and
degradation of YAP7,8. Thus, defects of the Hippo signalling
cause overgrowth phenotypes due to deregulation of proliferation
and apoptotic defects9,10. Hippo–YAP pathway is directly
involved in cancer development11–13, and inhibition of the YAP
activity provides a valuable route for cancer prevention and
treatment14–16. In current model, Hippo signalling is mainly
regulated via protein phosphorylation and degradation10,17.
Intriguingly, some key components of the Hippo–YAP pathway
undergo extensive regulation in RNA level through alternative
splicing (AS), a major mechanism to expand coding capacity of
human genome. For example, MST1 has multiple isoforms with
C-terminal truncations, and YAP has eight splicing isoforms with
different internal sequences18. However, the biological functions
of these isoforms are unclear.
AS elicits control over the major hallmarks of cancer19–21,
including apoptosis22, angiogenesis23 and epithelial–mesen-
chymal transition (EMT)24. However, the functional conse-
quences of most cancer-related splicing alterations are undefined.
AS is generally regulated by splicing factors that specifically bind
cis-elements in pre-messenger RNA (mRNA) to affect the
splicing efficiency25–27. The alteration of splicing factor levels
and activities is a main cause of splicing dysregulation in
cancer28–30. For example, a general splicing factor, RBM4,
functions as a potent tumour suppressor by controlling AS
events critical to cell proliferation, migration and apoptosis31,32.
Expression of RBM4 is significantly reduced in lung cancer and
strongly correlated with patient survival, making it a valuable
prognostic predictor.
Here we report that the Hippo pathway is under control of a
new splicing switch in TEAD4, producing a truncated isoform,
TEAD4-S, which lacks an N-terminal DNA-binding domain, but
maintains YAP interaction domain. TEAD4-S is located in both
the nucleus and cytoplasm, acting as a dominant negative isoform
to YAP activity. Splicing of TEAD4-S is facilitated by the tumour
suppressor RBM4. Consistently, TEAD4-S is reduced in cancer
cells, and its re-expression suppresses cancer cell proliferation and
migration, inhibiting tumour growth in xenograft mouse model.
Furthermore, TEAD4-S is reduced in human cancers, and
patients with elevated TEAD4-S levels have improved survival.
Altogether, these data reveal a splicing switch that serves to fine
tune the Hippo–YAP pathway. To our knowledge, this is the first
report that the Hippo–YAP pathway is regulated through RNA
splicing, which probably exemplify a new general regulatory
mode of cell proliferation in RNA level. We expect that splicing
misregulations of other genes in the Hippo–YAP pathway also
play critical roles in cancer development and thus should be
explored as new route of potential cancer therapy.
Results
Identification of an AS isoform of TEAD4. The transcription
factor-mediating YAP-dependent gene expression, TEAD4,
contains two functional domains: an N-terminal domain speci-
fically recognizing the enhancer of targeted genes through direct
binding of DNA and a C-terminal motif that interacts with
transcription co-activator YAP to promote transcription of target
genes33. On the basis of the annotation of the RNA sequencing
(RNA-seq) data, we discovered that the exon 3 of human TEAD4
can be skipped to generate a new isoform, producing a truncated
TEAD4 protein with an alternative start site at exon 6. This short
isoform of TEAD4 (TEAD4-S) lacks an N-terminal DNA-binding
domain, but still contains an intact C-terminal YAP-binding
motif (Fig. 1a; Supplementary Fig. 1a,b).
To validate the presence of this TEAD4-S isoform, we
measured the levels of TEAD4-S mRNA and protein in different
human tissues. While the full-length TEAD4 (TEAD4-FL)
represents the major form in all tested tissues, the TEAD4-S
mRNA is ubiquitously spliced with small tissue-specific variations
(Supplementary Fig. 1c). Consistently, using an antibody against
the common sequence of both TEAD4 isoforms (amino acids
151–261), we detected TEAD4-S protein in all tissues with
abundance comparable to a canonical isoform in some tissues
(for example, spleen and skeleton muscle; Supplementary
Fig. 1d). These two TEAD4 isoforms have distinct subcellular
localizations: while canonical TEAD4-FL is primarily located in
the nucleus, TEAD4-S is found in both the nucleus and cytoplasm
with no obvious preference (Fig. 1b). Importantly, both TEAD4
isoforms were found to bind YAP protein in a co-immunopre-
cipitation assay (Fig. 1c), supporting the finding that TEAD4-S
still contains an intact C-terminal YAP-binding motif.
Splicing of TEAD4-S is regulated by RBM4. To identify the
possible splicing factors that control the AS of TEAD4, we
analysed the sequence of exon 3 in TEAD4 and discovered a
putative RNA motif resembling a known binding site of RBM4
(CGGCCGG)34. RBM4 is a general splicing factor that functions
as a tumour suppressor in a number of human cancers31.
This observation raises the possibility that RBM4 may directly
control TEAD4 splicing. To test this possibility, we generated 293
cells that stably express RBM4 on tetracycline induction,
and found that RBM4 promotes the splicing of TEAD4-S in a
time-dependent manner (Fig. 1d; Supplementary Fig. 1e).
Such regulation is consistent across various cell types, as
overexpression of RBM4 increased the TEAD4-S mRNA and
protein levels in various cultured cancer cells from pancreatic,
lung, liver and breast cancers (Fig. 1e; Supplementary Fig. 1f).
Next, we generated a minigene reporter containing the exon
2–4 of TEAD4 (Fig. 1f, upper panel). Consistent with the previous
results in Fig. 1d,e, RBM4 expression indeed caused skipping of
exon 3 in this artificial reporter (Fig. 1f, lower-left panel).
Remarkably, a mutant splicing reporter destroying the putative
RBM4-binding site (mut 1, CTTATA) abolished the splicing
regulation of TEAD4 by RBM4, whereas another mutant reporter
with a replaced RBM4-binding motif (mut 2, GTAACG)35
restored the RBM4 regulation (Fig. 1f, lower-right panel).
We further confirmed that RBM4 directly bound to TEAD4
pre-mRNA using RNA-IP (Fig. 1g). Consistently, the mutant
RNA with the destroyed RBM4-binding site (mut 1) failed to
interact with RBM4, while the replacement of this site
with a different RBM4-binding sequence (mut 2) reinstated the
RNA–RBM4 interaction (Fig. 1h). Furthermore, we used
an antisense oligonucleotide (ASO3, TAATGGTGCCGGCCGT
GCCC) to block the RBM4-binding site in exon 3 of TEAD4. As
expected, RBM4 could no longer regulate TEAD4 splicing in the
presence of antisense oligos (Supplementary Fig. 1g). Collectively,
these data suggest that RBM4 indeed recognizes this putative
binding site to control TEAD4 splicing.
TEAD4-S antagonizes TEAD4-FL to repress YAP signalling.
Since TEAD4-S lacks the DNA-binding activity, it may lack the
ability to promote transcription and even compete with the
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canonical TEAD4 with its YAP-binding domain. We directly test
this hypothesis with a reporter system containing a luciferase
gene driven by a TEAD-dependent promoter36. We found that
expression of YAP alone or co-expression of YAP/TEAD4-FL
significantly increased luciferase activity, whereas co-expression
of TEAD4-S/YAP suppressed the gene activation in a dose-
dependent manner, suggesting that TEAD4-S has an opposite
activity to canonical TEAD4. Importantly, when increasing
amount of TEAD4-S was co-expressed with TEAD4-FL,
TEAD4-S can inhibit the transcriptional activity of TEAD4-FL
in a dose-dependent manner (Fig. 2a; Supplementary Fig. 2a). We
further demonstrated that TEAD4-S can directly disrupt the
binding of canonical TEAD4-FL to YAP as judged by reciprocal
co-immunoprecipitation assays (Fig. 2b,c; Supplementary Fig. 2b),
suggesting that TEAD4-S functions as a dominant negative
isoform via competing with TEAD4-FL. In addition, while
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TEAD4-FL is found to bind the promoter of its endogenous
target CTGF, TEAD4-S cannot bind the same DNA as judged by
chromatin immunoprecipitation, presumably due to lack of the
N-terminal DNA-binding domain (Fig. 2d; Supplementary
Fig. 2c). Together, these data suggest that TEAD4-S functions
as a dominant negative isoform.
In line with the finding that RBM4 promotes the splicing of
TEAD4-S, co-expression of RBM4 with YAP also reduced
TEAD4-mediated gene activation, whereas expression of RBM4
alone had no effect (Fig. 2a). This observation was further
supported by measuring the endogenous targets of YAP/TEAD4,
as co-expression of YAP/TEAD4-S diminished the YAP-depen-
dent activation of CTGF and ITGB in two different cell lines
(Fig. 2e,f; Supplementary Fig. 2d). Consistently, co-expression of
RBM4 with YAP can also reduced the activation of these two
genes by YAP (Fig. 2e,f), while expression of RBM4 alone had no
effect (Supplementary Fig. 2e), further confirming that RBM4-
mediated new TEAD4 splicing switch to control the YAP
signalling pathway.
To further assess the impact of the RBM4-mediated TEAD4
splicing switch on YAP signalling and cellular functions,
particularly cell proliferation, we conducted transcriptome
profiling by RNA-seq in cells transfected with YAP alone, YAP/
TEAD4-FL, YAP/TEAD4-S and YAP/RBM4 (Supplementary
Fig. 2f; Supplementary Data 1). As expected, cells with
co-expression of YAP with TEAD4-FL or TEAD4-S displayed
limited overlapping between significantly affected genes
(Supplementary Fig. 2g). Consistent with the finding that
RBM4 increases splicing of TEAD-S, the genes that were up- or
downregulated on YAP/TEAD4-S expression significantly overlap
with those altered in the same directions by YAP/RBM4
expression, whereas the genes altered in different directions are
mutually exclusive (Supplementary Fig. 2h; Po2.2 10 16 by
w2-test).
By comparing all samples with the vector-transfected control,
we identified a set of 429 YAP-activated genes that were enhanced
by co-expression of TEAD4-FL, but were repressed by
co-expression of TEAD4-S or RBM4 (Fig. 2g; Supplementary
Data 2). Amazingly, these genes form a densely connected
network as evaluated by the analysis of STRING database of gene
interaction (Fig. 2h). The largest cluster of genes contains many
key regulators of cell cycle, including transcription factor (for
example, E2F1 and Myc), some cyclins (for example, CCNB1 and
CCNE2) and genes required for chromatin alignment and
segregation (for example, NDC80, CDCA8, SPDL1 and CENPF).
In addition, the genes differentially regulated by two TEAD4
isoforms also include components in key signalling pathways that
affect cell proliferation (for example, CSNK2A1, PCNA and other
components of the Hippo pathway), as well as genes involved in
RNA splicing (for example, SMN2, SF3A2 and many splicing
factors) and translation (for example, eIF3C, eIF1B and ribosomal
proteins).
In addition, gene ontology analysis also suggested that the cell
cycle, cell proliferation and RNA processing are main functional
pathways that are activated by YAP YAP TEAD4, but
diminished by the non-canonical TEAD4 isoform
(Supplementary Fig. 2i). Taken together, these data indicate
that the short isoform of TEAD4 harbours functions to
antagonize conventional TEAD4, thus attenuating the Hippo–
YAP–TEAD signalling cascade.
TEAD4-S represses cancer cell proliferation and EMT. Hippo–
YAP pathway is known to control tumorigenesis10. The negative
regulation of this pathway by the short isoform of TEAD4
suggests that TEAD4-S may repress cancer cell proliferation. To
test this possibility, we measured the relative levels of TEAD4 in a
panel of lung cancer cells. We found that, while TEAD4-S is the
major isoform in the normal lung fibroblast and bronchial
epithelial cells (Fig. 3a; HFL1 and HBE), all tested lung cancer
cells have reduced TEAD4-S level compared with the normal cells
(Fig. 3a). Furthermore, in lung cancer cells with stable
overexpression of YAP alone or co-expression of YAP with
TEAD4-FL, TEAD4-S or RBM4 (Supplementary Fig. 3a),
TEAD4-S inhibited cell proliferation as compared with vector
or TEAD4-FL (Fig. 3b,c). Such inhibition was comparable to that
of RBM4 in both anchorage-dependent and -independent cell
growth in two distinct cancer cell lines (Fig. 3b,c).
Hippo–YAP signalling has also been shown to regulate the
EMT of cancer cells37,38. The inhibition of TEAD4-S to YAP-
activated cell proliferation makes us to speculate that it may also
repress the EMT. To test this, we examined whether the two
isoforms of TEAD4 have distinct impacts on the EMT. As shown
in Fig. 3d, co-expression of YAP/TEAD4-FL strongly induced
EMT in two primary tumour cell lines as judged by increased
levels of N-cadherin and Vimentin; however, the expression of
TEAD4-S or RBM4 suppressed the induction of EMT markers
(Fig. 3d). Interestingly, in H157 cells co-expressing YAP and
TEAD4-FL, the majority of YAP is retained in the nucleus as
pointed dots that are co-localized with TEAD4-FL (Fig. 3e;
Supplementary Fig. 3b). However, in cells expressing TEAD4-S,
the YAP is found in both nuclear and cytoplasmic compartments,
presumably through the interaction with TEAD4-S that is
diffused into the cytoplasm (Fig. 3e; Supplementary Fig. 3b).
Figure 1 | Identification of an alternative splicing isoform of TEAD4 regulated by RBM4. (a) Schematics of human TEAD4 pre-mRNA and protein. The
full-length TEAD4 contains 1–12 exons, including the DNA-binding domain in the N terminal, whereas exon 3 of TEAD4 can be skipped to generate a new
isoform whose translation is started at exon 6 to produce a truncated TEAD4-S protein. TEAD4-S lacks an N-terminal DNA-binding domain, but still
contains an intact C-terminal YAP-binding motif. (b) The localizations of TEAD4-FL and TEAD4-S were determined by immunofluorescence assay. Flag-
tagged TEAD4-FL or TEAD4-S was transfected into cells. The immunofluorescence assay was performed with anti-Flag antibody to show the localizations
of Flag-TEAD4. Scale bar, 25 mm. (c) Interaction of two TEAD4 isoforms with YAP protein as judged by co-IP experiment. The Flag-tagged TEAD4-FL or
TEAD-S was co-transfected with HA-tagged YAP into 293T cells, and the binding of YAP was detected. (d) 293 cells expressing RBM4 on tetracycline
induction were collected at different time points after induction to determine the expression levels of TEAD4-FL and TEAD4-S. (e) RBM4 regulates the
splicing of TEAD4 in various cancer cells, including PANC1, HT1080, MDA-MB-231 and HepG2. The cells were stably transfected with RBM4 or vector
control, and the splicing of TEAD4 was examined by RT–PCR. The representative gels were shown. (f) The schematic of TEAD4 pre-mRNA where the
potential RBM4-binding site (CGGCCGG) in red. TEAD4 splicing reporters with the indicated mutations (mut1: CTTATA and mut2: GTAACG) were
generated (upper panel). TEAD4 splicing reporters containing wild-type RBM4-binding site (lower-left panel) or mutations (lower-right panel) were co-
expressed with RBM4 or vector control in 293T cells to assay for the splicing change of TEAD4. Representative gels from triplicate experiments were
shown, with the mean±s.d. of TEAD4-S% plotted below representative gels. (g) Binding of TEAD4 pre-mRNAs with RBM4 was examined by RNA-
immunoprecipitation assay in cells exogenously expression FLAG-RBM4 or vector control. (h) 293 cells were co-transfected with Flag-RBM4 or vector
control and the indicated mutant or wild-type (WT) TEAD4 reporters, and then immunoprecipitated with anti-Flag antibody. The co-precipitated RNAs
were detected by RT–PCR.
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To further examine the functional role of TEAD4 splicing
switch, we applied a recently developed approach, engineered
splicing factors (ESFs)39–42, to specifically manipulate TEAD4
splicing and to test whether the splicing changes of TEAD4 can
directly affect YAP-mediated EMT and tumour proliferation. We
designed and generated a PUF domain that can specifically bind
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to an 8-nt RNA sequence (GAGCCTTG) in exon 3 of TEAD4,
and fused the designer PUF domain with a glycine-rich motif that
can inhibit exon inclusion on binding to pre-mRNA. The
resulting ESF, ESF-TEAD4, is designed to bind and inhibit the
inclusion of exon 3 in TEAD4, thus promoting the TEAD4-S
splicing (Fig. 4a). When transfecting ESF-TEAD4 in YAP stably
expressed lung cancer cells, H157 and A549, we found that the
ESF-TEAD4 specifically shifted TEAD4 splicing towards the
short isoform as compared with control ESF (Fig. 4b). As
expected, the splicing switch to TEAD4-S can indeed suppress the
YAP-mediated EMT (Fig. 4c) and the tumour cell proliferation
(Fig. 4d) in both lung cancer cell lines tested.
TEAD4-S inhibits tumour growth in vivo. To further assess
whether TEAD4-S affects cancer growth in vivo, we determined
whether expression of TEAD4-S could suppress tumour growth
in a xenograft mouse model. We generated H157 cells with stable
expression of YAP, YAP/TEAD4-FL, YAP/TEAD4-S or YAP/
RBM4, and injected these cells subcutaneously into the flanks of
nude mice to measure tumour growth. Consistent with our
in vitro results, cells expressing TEAD4-S developed smaller
tumours as compared with cells with YAP alone, YAP/TEAD4-FL
or even the vector control (Fig. 5a), suggesting that TEAD4-S
functions as an inhibitor of tumour development. In addition, the
xenograft tumours with TEAD4-S developed much slower than
cells with YAP, YAP/TEAD4-FL or even vector control (Fig. 5b),
further supporting that TEAD4-S inhibits cancer progression
in vivo. As a positive control, RBM4 also inhibited tumour
development in vivo, consistent with its role as antitumour
splicing factor to promote TEAD-S.
Next, we surgically collected paired non-small cell lung cancer
(NSCLC) samples and adjacent normal tissues from seven
patients, and measured the relative levels of two TEAD4 isoforms.
Compared with the paired normal tissues, the relative mRNA
levels of TEAD4-S were significantly reduced in six out of seven
primary NSCLC specimens (Fig. 5c), and the TEAD4-S protein
was substantially decreased in five out of seven specimens
(Fig. 5d), suggesting a general reduction of TEAD4-S expression
despite the obvious heterogeneity in different tumour specimens.
Intriguingly, in three of the NSCLC specimens (samples 4, 5 and
7), the truncated TEAD4-S protein was the predominant isoform
in normal tissues, but was almost completely eliminated in
tumours, implying that the AS switch in TEAD4 could play a
major role in the tumorigenesis of these patients.
To further evaluate the clinical relevance of TEAD4 splicing in
all cancers, we analysed the databases from TCGA consortium
that contains various large-scale RNA-seq results from thousands
of patients with various tumours43 (Supplementary Fig. 4a).
Strikingly, TEAD4-S levels were significantly altered in 7 out of 11
tumour types analysed with reduction in the majority of tumours
(6 out of 7; Fig. 5e), consistent with our results in the anti-
tumour activity of TEAD4-S. To further investigate the clinical
significance of TEAD4 splicing in cancers, we used a survival
analysis tool, Kaplan–Meier plotter, to analyse TCGA data sets
for the overall survival of various cancer patients with different
TEAD4-S levels. Strikingly, a higher level of TEAD4-S was
significantly associated with the improved overall survival in
patients with lung and colon cancers (Fig. 5f), and to a lesser
extent, in patients with liver and breast cancers (Supplementary
Fig. 4b, positive but non-significant association). These
observations indicate that TEAD4-S could be recognized as an
independent prognostic factor for the survival of cancer patients.
Collectively, this finding validated the mechanistic link between
the TEAD4-S isoform and cancer progression, highlighting the
importance of this splicing switch of the Hippo–YAP–TEAD
pathway in regulating human cancer progression and patient
survival.
Discussion
Extensive splicing misregulation is one of molecular hallmarks of
cancer44–47; however, the functional implication is far from clear.
Here we report a model in which the AS plays a key regulatory
role in mediating the activation of Hippo–YAP signals. In the
current model, activation of the Hippo pathway by multiple
extracellular cues is converged to its main effector YAP, whose
phosphorylation leads to cytoplasmic retention and protein
degradation. When unphosphorylated, YAP translocates into
the nucleus and interacts with transcription factors TEAD1–4 to
activate gene expression and promote cell proliferation10. We
demonstrated that the AS imposes a new layer of regulation:
skipping of exon 3 in TEAD4 produces a short isoform that
interacts and neutralizes YAP in both the nucleus and cytoplasm,
leading to the attenuation of YAP signalling (Fig. 4g). The
splicing of TEAD4-S is controlled by RBM4 through direct
binding to its pre-mRNA. Consistently, RBM4 and TEAD4-S
inhibit tumour progression in cultured cells and xenograft
tumours. Altogether, these data represent a new mechanism on
how the AS affects tumorigenesis through mediating the key
signalling cascades such as the Hippo–YAP pathway.
Genomic analyses of TCGA data sets indicate that splicing of
TEAD4 is commonly altered in cancer patients to reduce
TEAD4-S. Strikingly, re-expression of TEAD4-S significantly
reduced tumour development in cultured cells and mouse
model. Since the Hippo–YAP pathway has a broad impact on
Figure 2 | Antagonistic function of the two TEAD4 isoforms. (a) A luciferase reporter driven by CTGF promoter was co-transfected in the presence or
absence of YAP as indicated with TEAD4-FL, TEAD4-S or RBM4. The relative luciferase activities were determined by calculating the ratio of firefly
luciferase activities over Renilla luciferase activities. Three independent experiments were conducted, with the mean±s.d. of relative luciferase activities
were shown. (b) Expression vector of HA-YAP was co-transfected into 293T cells with Flag-TEAD4-FL, Flag-TEAD-S or Flag-TEAD4-FL in the presence of
untagged TEAD4-S, and the binding of HA-YAP was determined by co-immunoprecipitation (co-IP) experiment using anti-Flag antibody. (c) 293T cells
were co-transfected with Flag-TEAD4-FL, HA-YAP and increasing amounts of untagged TEAD4-S. The interaction between HA-YAP and Flag-TEAD4-FL
was determined by co-IP assay. The relative levels of two TEAD4 isoforms in these cells were determined by western blot using anti-TEAD4 antibody.
(d) H157 cells stably expressing TEAD4-FL or TEAD4-S were generated. Chromatin immunoprecipitation (ChIP) from these cells was performed with
control IgG and TEAD4 antibody. The precipitation of CTGF promoter was examined by PCR. (e,f) H157 and A549 cells stably expressing YAP, YAP/
TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 and control were generated. The expression of two YAP target genes, Ctgf and Itgb, was measured by real-time
PCR. The mean±s.d. of relative mRNA levels from triplicate experiments were plotted. (g) The transcriptomes of H157 cells expressing YAP, YAP/TEAD4-
FL, YAP/TEAD4-S or YAP/RBM4 were determined by RNA-seq. Using hierarchical clustering of all samples, we identified a subcluster of 429 genes that are
activated by YAP/TEAD4-FL, but the activation is eliminated by co-expression of YAP with TEAD4-S or RBM4. Relative expression levels are displayed
using Java TreeView. (h) The protein interaction networks of 429 genes were identified using the STRING database, and the highly connected groups were
defined by MCODE and displayed using Cytoscape. The hub proteins interacting with multiple clusters were coded with multiple colours, and the enriched
functions/gene ontology terms were labelled.
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Figure 3 | TEAD4-S reduces cancer cell proliferation and EMT. (a) RNA levels (upper panel) and protein levels (lower panel) of TEAD4-S in various
NSCLC lines and normal bronchial cells were measured by semi-quantitative RT–PCR and western blot. The mean±s.d. for the percentage of TEAD4-S
mRNA was plotted from three experiments. Each cancer cell line was compared with the two normal cell lines to calculate P values using Student’s t-test.
(b) H157 or A549 cells stably expressing YAP, YAP/TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 or vector control were analysed by colony formation assay. All
experiments were performed in triplicates, with mean±s.d. of relative colony numbers plotted (P values from t-test). Images of the whole plate were
shown. (c) H157 or A549 cells stably expressing YAP, YAP/TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 or vector control were analysed by soft agar assay. All
experiments were performed in triplicates, with mean±s.d. of relative colony numbers plotted (P values from t-test). (d) Western blot of epithelial and
mesenchymal markers was performed using lysates from indicated H157 and A549 stable cells. (e) The subcellular localizations of TEAD4-FL or TEAD4-S
with YAP. Cells were co-transfected with Flag-tagged YAP (red) and GFP-fused TEAD4 (green), and visualized with immunofluorescence assay. Scale bar,
25mm. The localization of TEAD4-FL and TAD4-S was quantified in transfected cells, and the per cent of cells with nuclear or cytoplasmic TEAD4 were
plotted (450 cells were captured and quantified in both samples).
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tumorigenesis and cancer development, modulating TEAD
splicing may provide a new approach for potential therapeutic
interventions of cancer. In particular, TEAD4-S is controlled by
RBM4, a master regulator of many cancer-related splicing events.
Activation of RBM4 increases the production of TEAD4-S, which
in turn may potentially inhibit tumorigenesis through multiple
oncogenic pathways.
We also noticed that the mRNA and protein levels of two
TEAD4 isoforms are not always consistent across different cell
lines and tissues (Figs 3a; and 5c,d), suggesting that the two
isoforms may be differentially controlled in the levels of protein
translation and/or degradation. This observation adds additional
layer of complexity in controlling TEAD4 isoforms in addition to
splicing regulation at RNA level. Adding to the complexity is the
YAP paralogue TAZ that also binds TEAD4 with similar affinity
(reviewed in ref. 48). We speculate that the two TEAD4 isoforms
may also differentially regulate TAZ-mediated branch of the
Hippo pathway; however, an additional research is required to
reveal the detailed mechanisms.
Human genome has four TEAD paralogues, TEAD1–4, all of
which can interact with YAP to promote transcription. The
N-terminal DNA-binding domains of all TEAD proteins are
highly conserved. On the basis of the sequence annotation,
TEAD2 and TEAD3 also have putative splicing variants with a
truncated N-terminal domain that in principal act similarly to
TEAD4-S (Supplementary Fig. 5), although it is unclear whether
these splicing isoforms are indeed translated. Our observations
that TEAD4-S functions as a dominant negative isoform to
sequester/neutralize YAP imply that it may also antagonize all
other TEAD paralogues. It is possible that this finding presents a
general regulatory switch of all TEAD proteins, and future studies
are warranted to fully address the role of all noncanonical TEAD
isoforms.
Multiple AS isoforms can also be found in other main
components of the Hippo–YAP pathway to differentially affect
cellular signals. For example, by skipping the exon 4, YAP can
produce a splicing isoform containing single WW domain
(YAP1-1). In contrast to the canonical isoform YAP1-2 that
contains two WW domains, the YAP1-1 does not bind
angiomotin and thus is not sequestered by angiomotin in the
cytoplasm49, In addition, YAP1-1 does not interact with p73 that
is the functional partner of YAP1-2 in response to the stress of
ultraviolet or serum depravation50. Our finding provides a
mechanistic link between Hippo signalling and AS regulation,
which may be a tip of the iceberg for a general regulatory mode.
Previously, the Hippo–YAP pathway is well known to be
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Figure 4 | The splicing switch to TEAD4-S inhibits EMTand cancer cell proliferation. (a) Schematics of the engineered splicing factor (ESF-TEAD4) that
regulates the splicing of TEAD4. PUF domain was engineered to recognize an 8-nt RNA sequence (GAGCCTTG) in exon 3 of TEAD4, and fused with a
glycine-rich motif of hnRNPA1 that can inhibit exon inclusion on binding to pre-mRNA. The resulting ESF, ESF-TEAD4, was designed to bind and inhibit the
inclusion of exon 3 in TEAD4, thus inducing splicing switch towards TEAD4-S. (b) ESF-TEAD4 or control ESF was transfected into YAP-expressing H157
and A549 cells. RNAs were extracted from the transfected cells, and the splicing of TEAD4 was examined with RT–PCR. The representative gel was shown.
The mean±s.d. for the percentage of TEAD4-S mRNA was plotted from three experiments. (c) Total proteins were purified from the same set of
transfected cells as in b, and the epithelial and mesenchymal markers were detected with western blots. (d) ESF-TEAD4 or control ESF was transfected into
YAP-expressing H157 or A549 cells. Colony formation assay was carried out to examine tumour cell proliferation. All experiments were performed in
triplicates, with mean±s.d. of relative colony numbers plotted (P values from t-test). Images of the whole plate were shown.
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controlled by a phosphorylation cascade that elicits rapid
regulation, the new control mode through splicing may present
a slower but more stable regulatory dynamics that is important
to cancer cell reprogramming. We speculate that splicing
misregulations of other components in the Hippo–YAP
pathway also play critical roles in cancer development,
and thus should be explored as a new route of potential cancer
therapy.
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Figure 5 | TEAD4-S can inhibit tumour growth in vivo. (a) H157 cells stably expressing YAP, YAP/TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 or vector control
were subcutaneously injected into the flank of nude mice. Each group contained nine mice. Pictures of the tumours removed after 17 days were shown.
Scale bar, 1 cm. (b) The growth of xenograft tumours was monitored and the average sizes of xenograft tumours were measured every 2 days (n¼9, error
bars indicate±s.d., Po0.05 by t-test). (c) Total RNA isolated from seven paired NSCLC tumours and adjacent normal tissues were assayed by semi-
quantitative RT–PCR. The mean±s.d. from three experiments was plotted. (d) TEAD4 levels from seven paired NSCLC tumours and adjacent normal
tissues were analysed by western blot. (e) The splicing alteration of TEAD4 was examined in various cancers by analysing the TCGA consortium containing
RNA-seq data sets from thousands of patients. The PSI of TEAD4 in the cancer or normal samples are presented as standard box plot, with the boxes
presenting the first and third quartiles and the whiskers representing the 2nd and 98th percentiles. ***Po 0.0005; **Po 0.005; *Po 0.05; and NS, not
significant. (f) The overall survivals of lung cancer and colon cancer patients with different ratios of TEAD4 splicing isoforms were analysed. (g) The model
of how the Hippo–YAP pathway is regulated through a TEAD4 splicing switch.
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Methods
Splicing reporter constructs. To construct the TEAD4 reporter, we used PCR
reactions to amplify a fragment containing exon 2, part of intron 2, exon 3, part of
intron 3 and exon 4 of TEAD4, and ligated this fragment to the pCDNA3-FLAG
vector digested with NheI/NotI. To generate TEAD4 reporters with mutated
RBM4-binding sites, Quikchange approach was applied with different paired
primers. All primers used in this study were listed in Supplementary Table 1.
ESF expression constructs. To express ESFs in cultured cells, we generated
expression constructs using the pCI-neo vector (Promega). We started with an
expression construct that encodes from N- to C terminal, FLAG epitope, Gly-rich
domain of hnRNP A1 (residues 195–320 of NP_002127), and the MS2 coat protein
(gift of Dr R. Breathnach form Institut de Biologie-CHR 1). The fragment encoding
the MS2 coat protein fragment was removed using BamHI/SalI digestion and
replaced with a fragment encoding a NLS (PPKKKRKV) and the PUF domain of
human Pumilio1, which was amplified using primers Pum-F1 and Pum-R1
(Supplementary Table 1). The resulting construct expresses a Gly-PUF-type ESF
under the control of a cytomegalovirus (CMV) promoter. To make ESF-TEAD4,
we introduced the point mutations in consecutive steps in the PUF domain to
make it recognize an 8-nt RNA sequence (GAGCCTTG) using a QuikChange Site-
Directed Mutagenesis kit (Stratagene) following the manufacturer’s instructions.
Human tissue total protein and cDNA panels. Human Tissue total protein and
complementary DNA (cDNA) panels were purchased from Amsbio Company.
Each panel contained 10 different human tissues, including the brain, colon, liver,
kidney, heart, lung, skeletal muscles, pancreas, spleen and stomach.
Cell culture and transfection. 293 FlpIn/T-Rex cells were purchased from Invi-
trogen. All other cell lines were purchased from American Type Culture Collection
(Manassas, VA, USA). The HEK293T human embryonic kidney, HeLa cervical
cancer, 293 FlpIn/T-Rex and PANC-1 human pancreatic carcinoma cell lines were
cultured in DMEM (high glucose) medium containing 10% fetal bovine serum
(FBS; Hyclone) and 1% penicillin/streptomycin (P/S). The A549 human lung
carcinoma cell line was cultured in F-12 K medium containing 10% FBS and 1%
P/S. The H157 human lung carcinoma cell line was cultured in RPMI-1640
medium containing 10% FBS and 1% P/S. The HT-1080 human fibrosarcoma
and HepG2 human hepatocellular carcinoma cell lines were cultured in Eagle’s
Minimum Essential Medium containing 10% FBS and 1% P/S. The MDA-MB-231
human breast cancer cell line was cultured in L-15 medium containing 10% FBS
and 1% P/S. The cell lines were tested for mycoplasma contamination using the
microbiological culture method, and all the lines were free of mycoplasma.
To generate stable cell line expressing RBM4 on tetracycline induction, we used
pCDNA5 FRT/TO vector and 293 FlpIn/T-Rex cells (Invitrogen). The FLAG-
tagged full-length RBM4 was cloned into the vector, and transfected with pOG44 in
1:9 ratio. The stably integrated cells were selected with 100mgml l of hygromycin
at 2 days after transfection for B2 weeks to obtain individual colonies. One day
before the induction, the cells were transferred to hygromycin-free medium. The
inductions were carried out by adding tetracycline to a final concentration of
2 mgml 1. The induced cells were collected at several time points after induction
to extract RNA and protein for further analysis.
To determine the localization of TEAD4-FL or TEAD4-S, HeLa cells were
plated onto a coverslip in six-well plates 1 day before transfection. An amount of
1 mg of GFP-tagged TEAD4-FL or TEAD4-S vectors was transfected using
lipofectamine 2000 according to the manual. After 48 h, cells were fixed for further
immunofluorescence analysis.
To stably express RBM4 (or other proteins) in PANC1 cells (or other cells), we
used lentiviral vectors. We transfected 293 cells with pCDH-flag-RBM4 or pCDH-
flag-empty vectors as per the manufacture’s protocols. The supernatant media
containing virus was collected by centrifugation to remove any cellular
contaminant. The resulting viral particles were used to infect H157 cells, and stably
integrated cells were selected by 5 mgml l of puromycin for 1 week. The
expression of transgenes was confirmed by western blots before further analysis.
To determine the effect of overexpression of RBM4 on TEAD4 splicing changes,
0.2 mg of TEAD4 mini-gene reporters was co-tranfected with 0.4 mg of RBM4, using
lipofectamine 2000 according to the manual. After 48 h, cells were collected for
further analysis of RNA and protein levels.
Assay of splicing with semi-quantitative RT–PCR. The total RNA was isolated
from transfected cells with TRIzol reagent (Invitrogen) according to the manu-
facturer’s instructions, followed by 1-h DNase I (Invitrogen) treatment at 37 C,
and then heat inactivation of DNase I. Total RNA (2 mg) was then reverse-tran-
scribed with SuperScript III (Invitrogen) using poly T primer, and one-tenth
of the room temperature product was used as the template for PCR amplification
(25 cycles of amplification, with trace amount of Cy5-dCTP in addition to
non-fluorescent dNTPs). Reverse transcription–PCR (RT–PCR) products were
separated on 10% polyacrylamide gel electrophoresis (PAGE) gels, and scanned
using a Typhoon 9400 scanner (Amersham Biosciences). The amount of each
splicing isoform was measured using ImageQuant 5.2.
Western blot. Cells were lysed in lysis buffer containing 50mM HEPES, 150mN
NaCl (4.38 g), 1mM EDTA, 1% (w/v) CHAPS and Sigma protease inhibitor
cocktail. Subsequently, the cell lysates were boiled in 2 SDS–PAGE loading
buffer for 10min, and then resolved by 10% SDS–PAGE and transferred to the
nitrocellulose membrane. All primary antibodies were diluted 1,000 times for
western blotting if not specified. The following antibodies were used in this study:
TEAD4 (#ab58310) antibody, anti-Myc tag antibody (#ab9106) and anti-HA tag
antibody (#ab9110) were purchased from Abcam; N-cadherin (#610921) antibody
was purchase from BD; Vimentin (#5741) and YAP (#12395) antibodies were
purchased from Cell Signaling Technology; and alpha-tubulin (#T5168, 1:5000
dilution) and FLAG M2 (#F1804) were purchased from Sigma-Aldrich. RBM4
antibody (#11614-1-AP) was purchased from Proteintech. Bound antibodies were
visualized using the ECL kit (GE Healthcare).
Clinical tissues samples collection. Fresh lung cancer tissues and normal
adjacent tissues were collected from patients with pathologically and clinically
confirmed lung carcinomas. All human tumour tissues were obtained with written
informed consent from patients or their guardians before participation in the
study. The Institutional Review Board of the Dalian Medical University approved
use of the tumour specimens in this study. All of tissue specimens were kept in
liquid nitrogen and sectioned for protein or mRNA extraction.
High-throughput mRNA-sequence and data analysis. RNAs from H157 cells
stably expressing YAP, YAP/TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 and control
vectors were purified using Trizol method, and subsequently cleaned using the
RNAeasy Kit (Qiagen). The RNAs were digested in column with RNAse-free
DNAse as per the manufacturer’s instruction. Total RNA not exceeding 3 mg was
further used to purify polyadenylated RNA using the Illumina TruSeq Total RNA
Sample Prep kits. We used the Ribo-Zero Human to remove the cytoplasmic
rRNA. The mRNA purified was further analysed using the Bioanalyzer (Agilent
Technologies) before generation of cDNA library with bar-coded ends. RNA-seq
libraries were robotically prepared using the Illumina TruSeq Total RNA Sample
Prep kits according to the manufacturer’s protocol. The RNA-seq data set was
deposited to the Gene Expression Omnibus with accession number GSE80372.
To estimate the gene expression levels, we used RSEM package and bowtie2
(refs 51,52) to align all reads to human reference genome (UCSC hg19 version).
Then, we provided a fragment length distribution with options of ‘–fragment-
length-mean 75’ and ‘–fragment-length-sd 10’ to calculate transcript expression
levels. Subsequently, we used EBSeq tool53 to examine differential expression genes
of pair-wise comparison based on empirical Bayesian methods.
Heat map. We included genes that met the following criteria: (i) FPKM (fragments
per kilobase of transcript per million mapped reads) values of a given gene are not
equal in all samples; (ii) at least one of the FPKM values in all samples is Z3; and
(iii) the ratio of the maximum FPKM value and the minimum FPKM value in all
samples isZ2. Then, we used the log 2 ratio of FPKM values of the included genes,
normalized by the FPKM value of control sample, as input of Cluster 3.0 (ref. 54).
We clustered the data set using the hierarchical clustering method based on
Pearson correlation with average linkage, and further viewed the results using
Java TreeView.
We selected the cluster in this pattern—upregulated by YAP–TEAD434, but
downregulated by YAP–TEAD305 and YAP–RBM4—as our target data set. This
data set includes the genes that are differentially regulated by TEAD4 isoforms. The
heat map shown is ordered by the FPKM value of YAP.
The gene ontology analysis was performed using DAVID gene ontology analysis
software to search for enriched pathways. The functional association of TEAD4
targets were analysed using the protein interaction data from STRING database,
generating a set of functional interaction networks. The sub-network containing
more than five nodes were demonstrated.
Soft agar assay. Equal volumes of 1.2% agar and 2 DMEM (or RPMI-1640)
mediums were mixed and placed onto six-well dishes to generate 0.6% base agar.
A549 cells (or H157 cells) expressing YAP, YAP/TEAD4-FL, YAP/TEAD4-S,
YAP/RBM4 and control vectors were seeded in 0.3% top agar (104 cells per plate)
and incubated at 37 C in humidified atmosphere for 3 weeks. Colonies were
stained with crystal violet and counted.
Colony formation assay. A549 cells (or H157 cells) expressing YAP, YAP/
TEAD4-FL, YAP/TEAD4-S, YAP/RBM4 and control vectors (5,000 cells per dish)
were seeded in the 10-cm dishes and incubated at 37 C in humidified incubator for
2 weeks. Colonies were fixed and stained with crystal violet, and the number of
colonies was counted.
Xenograft assays. Forty-five 4-week-old female BALB/c nude mice were
purchased from Vital River Laboratories for in vivo tumorigenicity study. The
Institutional Animal Care and Use Committee of the Dalian Medical University
approved the use of animal models in this study. Mice were injected
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subcutaneously with 1 106 H157 cells expressing YAP, YAP/TEAD4-FL, YAP/
TEAD4-S, YAP/RBM4 and control. Nine mice were used for each group. Mice
were raised in the following 3 weeks. The mice were then monitored for tumour
volume and overall health. The size of the tumour was determined by caliper
measurement of the subcutaneous tumour mass every 3 days. Tumour volume was
calculated according to the formula (4/3)pr12r2, (r1or2). Each experimental group
contained nine mice. At the end of 17 days, all mice were killed, and tumours were
removed for further analysis. For all data points, three independent measurements
were performed and means were used for calculation.
RNA immunoprecipitation. 293T cells (1 106) expressing RBM4 or control
vector are collected and washed twice with 10ml of PBS, and then resuspended in
10ml of PBS. Formaldehyde (37% stock) is added to the above solution to a final
concentration of 1% and incubated at room temperature for 10min with slow
rotating. Crosslinking reactions are quenched by the addition of glycine solution
(pH 7.0) to a final concentration of 0.25M, followed by incubation at room
temperature for 5min. The cells are collected by centrifugation at 700g for 4min at
4 C, followed by two washes with ice-cold PBS. Fixed cells are resuspended in 2ml
of radioimmunoprecipitation assay (RIPA) buffer (50mM Tris-Cl, pH 7.5, 1% NP-
40, 0.5% sodium deoxycholate, 0.05% SDS, 1mM EDTA, 150mM NaCl) con-
taining protease inhibitors. The cells are subsequently lysed by three rounds of
sonication. Insoluble material is removed by microcentrifugation at 16,000g for
10min at 4 C. An aliquot of solubilized cell lysate is mixed with protein A–
Sepharose beads along with nonspecific competitor tRNA. This mixture is rotated
for 1 h at 4 C, followed by microcentrifugation at 1200g for 5min. The supernatant
is removed and used for immunoprecipitation.
Protein A or protein G–Sepharose beads are coated with the Flag antibody for
2 h at 4 C, followed by extensive washing with RIPA buffer containing protease
inhibitors. Before immunoprecipitation, the beads are incubated for 10min in
RNasin. The precleared lysate is diluted with RIPA buffer, mixed with the
antibody-coated beads and incubated with rotation for 60–90min. The beads are
collected using a minicentrifuge at 2800g for 45 s. The beads are washed five or six
times with 1ml of highstringency RIPA buffer (50mM Tris-Cl, pH 7.5, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS, 1mM EDTA, 1M NaCl, 1M urea, 0.2mM
phenylmethyl sulphonyl fluoride) by 10-min rotation at room temperature. The
beads containing the immunoprecipitated samples are collected and resuspended
in 100ml of 50mM Tris-Cl, pH 7.0, 5mM EDTA, 10mM dithiothreitol and 1%
SDS. Samples (resuspended beads) are incubated at 70 C for 45min to reverse the
crosslinks. The RNA is extracted from these samples using Trizol according to the
manufacturer’s protocol, and reverse-transcribed into cDNA for PCR detection.
Immunofluorescence staining. To determine the localization of TEAD4-FL,
TEAD4-S and YAP, we performed immunofluorescence assay. In brief, cells were
plated on coverslips to appropriate density. Transfected cells were fixed on the
coverslips with 4% paraformaldehyde in 1 PBS for 15min at room temperature
and washed with 1 PBS three times. Cells were then permeabilized with 0.2%
Triton X-100 for 10min. After blocking in 3% bovine serum albumin for 30min,
slides were incubated with indicated antibodies (Flag or Myc, 1:100 dilution)
antibody diluted in 1% bovine serum albumin for 2 h. Subsequently, slides were
washed with 1 PBS for three times, and then incubated with fluorophore-
conjugated secondary antibodies for 1 h. The coverslips were then washed
and mounted with mounting medium (Vector shield’s mounting medium
with 4,6-diamidino-2-phenylindole). Cells were visualized using an Olympus
fluorescence microscope, and photographs were generated using a Kodak digital
camera.
Luciferase reporter assay. For the luciferase reporter assay, HEK293T cells
were seeded in 24-well plates. Cells were co-transfected with 100 ng of CTGF
promoter/firefly luciferase reporter plasmid and different amount of YAP (100 ng),
TEAD4-FL (100 ng), TEAD4-S (20 or 100 ng), 100 ng TEAD4-FL with increasing
amounts of TEAD4-S (20, 50 and 100 ng) and RBM4 (100 ng) plasmids and 5 ng of
pRL-TK Renilla plasmids using lipofectamine 2000 (Invitrogen). After 48 h of
transfection, cells were either lysed in protein lysis buffer for protein extraction
or in passive lysis buffer (Promega) for luciferase assay measured with the
Dual-Luciferase Reporter Assay System (Promega), using the TD-20/20
Luminometer (Turner Designs). The relative luciferase activities were determined
by calculating the ratio of firefly luciferase activities over Renilla luciferase
activities.
Assay of CTGF and ITGB expression with real-time PCR. The real-time PCR
was performed using the Maxima SYBR Green qPCR Master Mix (Thermo
Scientific) and a 7500 real-time PCR system (Life Technologies) according
to the manufacturer’s instructions. The expression level of CTGF and ITGB was
normalized to the endogenous expression of GAPDH.
Statistics. Statistical analyses of colony formation, soft agar and splicing changes
were performed using Student’s t-test.
Data availability. RNA-seq data that support the findings of this study have been
deposited in Gene Expression Omnibus of NCBI with the accession code
GSE80372. The authors declare that all the data supporting the findings of this
study are available within the article and its Supplementary Information files.
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